Market Newsdesk

NEW BRUNSWICK, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) — Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”), a privacy-first social media and technology innovator, today announced that it was granted and issued a new U.S. patent that further expands and strengthens its secure streaming and content sharing technology. U.S. Patent # 12,524,507, issued by the U.S Patent and Trademark Office (USPTO), is titled “Secure Web RTC Real Time Communications Service for Audio and Video Streaming Communications.”

“This U.S. patent is an important expansion of our intellectual property protection for the new peer-peer communications technology under continuing development for Myseum’s social platforms,” said Darin Myman, Chief Executive Officer of Myseum. “Maximized privacy has always been central to our platform architecture, and the expanded claims provide additional, long-term protection for our newest innovation—and now our flagship platform—Picture Party by Myseum.”

The new patent covers Myseum’s audio and video streaming communications and content sharing platform that securely connects multiple users using a push-button WebRTC chat app connection over a peer-to-peer (P2P) network. The Company’s Secure Real Time Communications Service (SRTCS) uniquely combines advanced security technologies to provide user-based permissions control when communicating and sharing rich media content with other users including end-to-end encryption (E2EE), hash technology (DHT), and digital rights protection (DRM). SRTCS has also designed a unique cloud based streamed video storage and sharing platform service for consumers and businesses for video storage and sharing applications.

Myseum now holds 19 patents in the U.S. and other countries.

Picture Party by Myseum is available for download in the iOS app store and Google Play store. Videos are available on the Picture Party by Myseum channel on YouTube. Visit pictureparty.com for details.

About

Picture Party by Myseum

Picture Party by Myseum introduces a new way to make sharing photos and videos easier, a lot more fun, and private. Picture party is much more than a shared album; it’s a complete personal and private social network with a live feed that updates instantly as all your guests’ posts. You can share a post with dozens of pictures, comment and react. It even organizes your photos in an album, or you can relive the Picture Party with all the comments and posts as they happened. Unlike group chats that are unorganized, no matter when you join the Picture Party, you can see everything from the beginning. Picture Party makes it easier and more fun to share with the people right next to you, or anywhere in the world.

Picture Party solves everyday sharing frustrations by eliminating the common headaches of modern photo sharing:

• No more passing around your phone for others to view your photos and videos.
• No more crowds gathering over your shoulder to see a clip.
• No more debating whether to text, drop, email, or tag group photos.
• No more struggling with social media privacy, data exposure, or AI training risks.

Whether you’re at a family gathering, wedding, sporting event, vacation, concert, school function, or business meeting, everyone becomes a photographer, and no moment is missed. Instantly share group shots without ever chasing people for their copies again.

How it works:

Picture Party lets users instantly create private, encrypted spaces — called Picture Parties — to share photos and videos in curated, personal feeds.

Users can:

• Create unlimited Picture Parties.
• Invite anyone via text, QR code, or in-app invite.
• Launch a Picture Party (a timed or ongoing shared event) in under a minute.
• Add titles, comments, and reactions to posts.
• Maintain complete control over privacy, interaction settings, and who can view or contribute.

Privacy:

The only people that can see your pictures are the ones who you invited to the picture party. All your media and texts are private and encrypted. You decide if pictures can be saved by your guests or who can invite people to the party.

The technology underpinning Picture Party by Myseum is supported by a newly allowed U.S. patent. The patent covers the core personal and private social networking architecture behind Picture Party and represents a significant milestone in Myseum’s intellectual property strategy. The Company believes the new IP is foundational to a new category of private social interaction and a key driver of long-term platform value.

About Myseum, Inc.

Myseum, Inc. (formerly DatChat Inc.) is a privacy and social media technology company focused on innovative and creative user platforms. Its flagship platform is Picture Party by Myseum, a next-generation social sharing platform that makes it easier to share your photos and videos both today, and for generations to come. Myseum’s innovative social media platform brings a fresh and needed approach to digital media and content management, allowing users to create a digital legacy that makes it easier to share both today, and with future generations. The platform is backed by both patented technology and proprietary software.

The Company also operates the DatChat Messenger & Private Social Network, which presents technology that allows users to change how long their messages can be viewed before or after users send them, prevents screenshots, and hides encrypted photos in plain sight on camera rolls. The patented technology offers users a traditional texting experience while providing control and security for their messages. With the DatChat Messenger, a user can decide how long their messages last on a recipient’s device while feeling secure that at any time, and delete individual messages or entire message threads, making it like the conversation never happened.

Visit Myseum.com and datchat.com/investors for more information.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at https://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact

[email protected]

800-658-8081

This clearance
enables
the next phase of development aimed
ultimately
at removing the adjunct
use
in the US

The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis scan, enabling both 3D and 2D views from a single scan, without exposing the patient to any additional radiation

PETACH TIKVA, Israel – February 3 – NANO-X IMAGING LTD (“Nanox” or the “Company”) today announced that the United States Food and Drug Administration (FDA) has granted 510(k) clearance for TAP2D, a new cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. This clearance marks an important step in Nanox’s regulatory strategy to position its tomosynthesis systems as primary diagnostic solutions and advances the Company’s commitment to increased access to innovative medical imaging solutions.

The newly cleared enhancement capability provides radiologists with an additional, clear 2D view, generated from the digital tomosynthesis scan. The feature is designed to support evaluation while maintaining a smooth workflow for users. The additional view is automatically delivered within the existing clinical environment without adding complexity for clinicians or operators.

The Nanox.ARC and Nanox.ARC X are FDA cleared, multi-source digital tomosynthesis systems that utilize advanced 3D imaging technology to provide enhanced diagnostic capabilities at a lower cost and radiation dose than traditional systems.

The Nanox.ARC systems’ software upgrades and new capabilities, such as TAP2D, can be added remotely to the Nanox.ARC systems, following this and future regulatory clearances.

“We are pleased to receive FDA clearance for TAP2D,” said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. “This clearance provides important regulatory insights as we work toward our goal of removing the adjunctive use in the United States, which would allow the Nanox.ARC to serve as a standalone primary imaging solution as it already does in Europe under our CE Mark certification. We remain focused on delivering innovations that elevate patient care and broaden access to high quality imaging around the world.”

Nanox plans to make the newly cleared enhancement software available to existing installations as part of its ongoing rollout of imaging improvements.

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:

Ben Shannon
ICR Healthcare
[email protected]

Investor Contact:
Mike Cavanaugh
ICR Healthcare
[email protected]

MINNEAPOLIS, MN, Feb. 03, 2026 (GLOBE NEWSWIRE) —
Sharplink, Inc. (formerly SharpLink Gaming, Inc.) (Nasdaq: SBET) (“Sharplink” or the “Company”), one of the world’s largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today announced that it has officially changed its corporate name to Sharplink, Inc., effective February 3, 2026.

The name change reflects the Company’s continued evolution and broader strategic focus. The change was effected through an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, filed with the Secretary of State of the State of Delaware.

The Company’s business operations, capitalization, board of directors and executive leadership remain unchanged as a result of the name change.

About Sharplink, Inc.

Sharplink, Inc. (Nasdaq: SBET) is one of the world’s largest publicly traded companies to adopt ETH as its primary treasury reserve asset – a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world’s leading smart-contract platform and second largest digital asset. Learn more at www.sharplink.com.

Forward-Looking Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and these forward-looking statements are subject to various risks and uncertainties. Such statements include, but are not limited to, goals and expectations regarding the Company’s strategy and potential partnerships, and other statements accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, but the absence of these words does not mean that a statement is not forward-looking. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to repurchase additional shares of SharpLink’s common stock through its stock repurchase program, potential use of the Company’s ATM facility, the Company’s ability to achieve profitable operations, fluctuations in the market price of ETH that will impact the Company’s accounting and financial reporting (see accounting rules discussed below), government regulation of cryptocurrencies and online betting, changes in securities laws or regulations, customer acceptance of new products and services, the demand for its products and its customers’ economic condition, the impact of competitive products and pricing, the lengthy sales cycle, proprietary rights of the Company, changes in applicable laws or regulations, and its competitors, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the SEC. Under U.S. generally accepted accounting principles, entities are generally required to measure certain crypto assets at fair value, with changes reflected in net income each reporting period. Changes in the fair value of crypto assets could result in significant fluctuations to the balance sheet and income statement results. Additionally, for other certain types of crypto assets, the Company uses the historical costs less impairment model. This model may require the Company to record an associated impairment charge reflected in net income as a result of a decrease in the market price of the crypto assets below the cost value at which the Company’s crypto assets are carried on its balance sheet. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company does not undertake any responsibility to update the forward-looking statements in this press release.

CONTACT:

SharpLink’s Investor Relations Contact:
Sean Mansouri, CFA or Aaron D’Souza | Elevate IR
Phone: (720) 330-2829
Email: [email protected]

SharpLink’s Media Contact:
Email: [email protected]

Caylent Named Development Partner to Lead AWS-Native Build

Roseland, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) — Gaxos.ai Inc. (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various high-growth sectors, today announced that Amazon Web Services (“AWS”) has committed to fund the preliminary development of Gaxos Labs’ innovative, AI-powered sales coaching platform, positioning Gaxos to compete in the multibillion- dollar sales technology market.

The AWS-backed initiative, in collaboration with Caylent, an AWS premier partner, supports the development of a real-time, AI sales platform designed for enterprise-scale deployment, incorporating live call transcription, automated coaching intelligence, and post-call analytics. The platform is being built for full AWS-native infrastructure, enabling rapid scalability, low-latency, and commercial readiness. The engagement focuses on consolidating and prototyping core platform capabilities and proprietary frameworks on AWS to support advanced workloads, with an emphasis on scalable infrastructure design, security, governance controls, and operational efficiency, while reducing reliance on external providers.

“AWS funding our platform development is a major validation event for Gaxos,” said Vadim Mats, CEO of Gaxos. “This collaboration materially advances our roadmap and enhances our ability to pursue large-scale commercial opportunities.”

Gaxos expects the AWS-supported development phase to enhance credibility, support future revenue-generating opportunities, and open the door to additional strategic partnerships.

For more information, visit Gaxos Labs. You can also follow Gaxos Labs on X, Facebook, or Gaxos.ai on LinkedIn for the latest updates and news. 

About Amazon AWS

Amazon Web Services is the world’s most comprehensive and broadly adopted cloud, enabling customers to build almost anything they can imagine. Amazon AWS offers the greatest choice of innovative cloud and AI capabilities and expertise, on the most extensive global infrastructure, with industry-leading security, reliability, and performance.

About Caylent

Caylent is a cloud services company helping organizations modernize applications, migrate workloads, and build cloud-native platforms. Caylent works with enterprises and high-growth companies to design and implement secure, scalable, and high-performance AWS solutions, enabling faster innovation and operational efficiency. Caylent’s achievements include being named AWS Migration Consulting Partner of the Year, GenAI Industry Solution Partner of the Year, and Industry Partner of the Year – Financial Services in 2024, Application Modernization Partner of the Year in 2023, AWS Innovation Partner of the Year in 2022, and AWS Rising Star Partner of the Year in 2021. Caylent’s services include migrations, modernization, custom software development and generative AI.

About Gaxos.ai Inc.

Gaxos.AI isn’t just developing applications; it’s redefining the human-AI relationship. Our offerings span health and wellness as well as gaming. We’re committed to addressing health, longevity, and entertainment, through AI solutions.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Gaxos.ai Inc. Company Contact

Investor Relations
E:[email protected]
T: 1-888-319-2499

Collaboration
combines Iron Brain’s self-learning AI for defense applications with Maris-Tech’s advanced edge computing solutions

Rehovot, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in video and artificial intelligence (“AI”)- based edge computing technology and Iron Brain Ltd. (“Iron Brain”), a provider of advanced AI solutions for defense applications based on a revolutionary self-learning approach, today announced a new collaboration for the integration of Iron Brain’s AI tools into Maris-Tech’s edge computing platforms.

The combined solution will allow advanced AI capabilities on small and unmanned platforms that could not previously support legacy AI, as well as improve AI performance on ground situational awareness and terrain dominance platforms.

“Our collaboration with Iron Brain will significantly improve the AI performance of Maris-Tech’s products already deployed on drones, armored vehicles, and other defense applications,” said Israel Bar, Chief Executive Officer of Maris-Tech. “We believe that these combined solutions have the potential to open new opportunities for advanced video and AI defense solutions at the edge.”

“Our adaptive, self-learning AI is designed to deliver real-time battlefield intelligence on platforms with limited computing resources,” said Moshe Kravitz, Chief Executive Officer of Iron Brain. “By integrating with Maris-Tech’s edge solutions, we will be able to bring advanced multi-sensor AI capabilities to unmanned systems and other mission-critical defense applications.”

About Maris-Tech Ltd.

Maris-Tech is a global leader in video and AI-based edge computing technology, pioneering intelligent video transmission solutions that conquer complex encoding-decoding challenges. Our miniature, lightweight, and low-power products deliver high-performance capabilities, including raw data processing, seamless transfer, advanced image processing, and AI-driven analytics. Founded by Israeli technology sector veterans, Maris-Tech serves leading manufacturers worldwide in defense, aerospace, Intelligence gathering, homeland security (HLS), and communication industries. We’re pushing the boundaries of video transmission and edge computing, driving innovation in mission-critical applications across commercial and defense sectors.

For more information, visit https://www.maris-tech.com/

About Iron Brain Ltd.

“IronBrain develops adaptive AI solutions for defense and intelligence applications using a proprietary self-learning approach. Its technology enables military systems to recognize new targets and threats with minimal training data, without the lengthy retraining cycles required by conventional AI. Built on IronBrain’s signature-generation technology and backed by Israel Aerospace Industries (IAI), IronBrain delivers real-time multi-sensor intelligence across EO, SAR, IR, and SIGINT environments, including on small and unmanned platforms operating at the edge

For more information, visit https://www.ironbrain.ai/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect”,” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing the benefits of the new collaboration between the Company and Iron Brain’s AI, the potential of the collaboration to open new opportunities for the Company’s advanced video and AI defense solutions, and that the collaboration will bring advanced multi-sensor AI capabilities to unmanned systems and other mission-critical defense applications. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
[email protected]

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Richtech Robotics Inc. (NASDAQ: RR) publicly traded securities between January 27, 2026 and 12:00 p.m. EST on January 29, 2026, inclusive (the “Class Period”), have until April 3, 2026 to seek appointment as lead plaintiff of the Richtech Robotics class action lawsuit. Captioned Diez v. Richtech Robotics Inc., No. 26-cv-00231 (D. Nev.), the Richtech Robotics class action lawsuit charges Richtech Robotics and certain of Richtech Robotics’ top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Richtech Robotics

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-richtech-robotics-inc-class-action-lawsuit-rr.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Richtech Robotics develops, manufactures, deploys, and sells robotic solutions for automation in the service industry.

The Richtech Robotics class action lawsuit alleges that throughout the Class Period Richtech Robotics claimed that it had a collaborative and commercial relationship with Microsoft when it did not.

The Richtech Robotics class action lawsuit further alleges that on January 29, 2026 at 12:00 p.m. EST, Hunterbrook Media published an article entitled “Breaking: Microsoft Denies Partnership with Richtech Robotics,” which alleged that “‘Richtech participated in an AI Co-Innovation Lab engagement, which is a standard customer engagement focused on exploring and prototyping AI solutions using Microsoft technologies . . . . There is no commercial element in this lab engagement.’” On this news, the price of Richtech Robotics Class B stock fell more than 29% over two trading days, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Richtech Robotics publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Richtech Robotics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Richtech Robotics investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Richtech Robotics shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Richtech Robotics class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]

LAS VEGAS, Feb. 03, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) reports that consumer intent to purchase vehicles remains strong for 2026, with four in ten U.S. adults planning to buy a car, most within the next year. The company announced these findings today at the 2026 AFSA Vehicle Finance Conference in Las Vegas. TransUnion surveyed 3,076 U.S. consumers age 18 and older. Among them, 1,190 respondents say they intend to buy a vehicle—39% of the total sample—showing that vehicle purchases rank high on consumers’ priority lists.

More than 80% of consumers who indicated intent to buy a vehicle expect to purchase within the next 12 months. This trend holds across all generations. Additionally, 65% of prospective buyers expect to trade in their current vehicle, which supports the market for used cars.

“New vehicle purchases remain a clear priority for consumers, with more than a third of those surveyed planning to buy a car within the next 12 months,” said Jason Laky, executive vice president and head of financial services at TransUnion. “This intent to purchase points to solid underlying market demand and could meaningfully increase used‑car supply as shoppers replace existing vehicles.”

Among consumers planning a vehicle transaction, 87% intend to buy, and 13% intend to lease. Younger generations express greater interest in leasing—17% of Gen Z and Millennials compared with 7% of Baby Boomers—reflecting a preference for flexibility and lower upfront and ownership costs.

These leasing trends emerged as auto loan originations began to rise in 2025, driven by anticipation of tariffs and, to a lesser extent, the end of the EV tax credit. Super prime and subprime segments led this growth, despite ongoing challenges related to affordability.

Affordability remains the most significant obstacle for consumers not planning to buy: 53% cite cost concerns, and 44% cite economic uncertainty. Whether these barriers lessen will depend on the direction of vehicle prices, interest rates and improving consumer confidence.

Traditional Gas Vehicles Still Lead, but Hybrid and EV Interest Continues to Grow

Half of prospective buyers indicated they intend to purchase a traditional gas-powered vehicle compared to 33% for hybrids and 16% for electric vehicles (EVs). Millennials show a slight preference for hybrids over gas-powered vehicles, while Gen Z favors traditional gas models. Still, nearly half of all respondents say they remain open to considering an EV in the future.

Consumers interested in EVs cite lower fuel costs (72%), environmental benefits (66%) and new technology features (62%) as key reasons. Those who do not consider EVs cite preference for combustion engines (51%), range anxiety (41%), limited charging infrastructure (34%) and price concerns (37%).

Older consumers considering future EV purchases emphasize fuel savings and environmental benefits, whereas Gen Z places additional value on advanced technology and features.

“Internal combustion powertrains still dominate because affordability and charging infrastructure continue to challenge EV adoption,” said Satyan Merchant, senior vice president of auto and mortgage business leader at TransUnion. “Millennials show increasing interest in hybrids, while Gen Z leans toward traditional gas vehicles—likely due to affordability constraints. Audience segmentation and credit-based targeting tools enable lenders to pinpoint affordability-driven consumers across generations who are most likely to be ready to enter the auto market in the near term.”

For more insights and to learn how TransUnion Automotive Solutions can help auto lenders reach the right consumers with precision, click here.

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

http://www.transunion.com/business

Contact	Dave Blumberg TransUnion
E-mail	[email protected]
Telephone	312-972-6646

Company highlights accelerating access and revenue growth for ARBLI

^™

and confirms REZENOPY

^™

launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million

Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter

COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC.
(NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial update on ARBLI^™ (losartan potassium) oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook—including reaffirming its plan to commercially launch REZENOPY^™, a life-saving opioid overdose emergency treatment, in the second quarter of 2026.

Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to ARBLI^™ across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions (IQVIA MAT Dec 2025) U.S. losartan market.

Key highlights:

• Secured multiple PBM-led GPO rebate agreements, supporting expanded commercial coverage and formulary placement for ARBLI^™
• Executed multiple Institutional GPO agreements, expanding U.S. access to more than 2,500 healthcare institutions nationwide
• Achieved formulary inclusion with major national health plans, expanding coverage to over 100 million covered lives
• Established a strategic collaboration with BlinkRx, enhancing patient access, fulfillment, and adherence through a streamlined digital pharmacy and hub service platform

“These milestones significantly expand the commercial opportunity for ARBLI^™ and represent an important inflection point in its launch trajectory,” commented Narasimhan Mani, President and co-CEO of Scienture. “By securing GPO agreements, expanding formulary inclusion, and partnering with BlinkRx, we are significantly increasing the number of patients and providers who can readily access ARBLI^™.”

Looking ahead to the first quarter of 2026, Scienture expects:

• Continued sequential growth in ARBLI^™ prescription volumes and product adoption
• Improved commercial efficiency, as early launch investments translate into recurring demand
• Further expansion of payer and pharmacy engagement, supporting broader patient access across commercial and government sectors

“We are encouraged by the steady progress we’ve made with ARBLI^™ since launch,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “The last four months have validated the unmet need for a ready-to-use oral suspension of losartan, and we believe Q1 2026 will reflect the momentum we’ve built across prescriber adoption, distribution, and patient demand.”

Scienture reaffirms its plan to commercially launch REZENOPY^™, a life-saving opioid overdose emergency treatment in the second quarter of 2026, representing the Company’s second product launch in the US market for naloxone (IQVIA MAT Dec 2025 of $143 million and 9.2 million (eaches) in total annual sales and volume respectively). Management believes REZENOPY^™ will leverage Scienture’s expanding commercial infrastructure and access footprint established through ARBLI^™.

“Our progress with ARBLI^™ has laid the groundwork for a scalable, multi-product commercial platform. With REZENOPY^™ planned for launch in the first quarter of 2026, we believe Scienture is entering its next phase of growth. Importantly, during Q4 2025, we fundamentally strengthened our balance sheet through a substantial reduction in outstanding debt and a meaningful improvement in our cash resources . As of December 31, 2025, the Company had a cash position of approximately $7.0 million. With an optimized capital structure, we believe we are now well positioned and adequately capitalized to execute our commercial strategy, support the continued growth of ARBLI^™, and advance our key operational and pipeline objectives,” concluded Narasimhan Mani, President and co-CEO of Scienture.

About ARBLI

^™

ARBLI^™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. ARBLI^™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, ARBLI^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, ARBLI^™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. ARBLI^™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

ARBLI^™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. ARBLI^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

ARBLI^™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take ARBLI
  
  ^™
  
  when pregnant. When pregnancy is detected, discontinue ARBLI
  
  ^™
  
  as soon as possible.
  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ARBLI^™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer ARBLI^™ with aliskiren in patients with diabetes. Avoid use of aliskiren with ARBLI^™ in patients with renal impairment (GFR <60 mL/min).
• Do not administer ARBLI^™ in patients with severe hepatic impairment. ARBLI^™ has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About REZENOPY

^™

REZENOPY^™ (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.

REZENOPY^™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT SAFETY INFORMATION

• Administration: REZENOPY^™ nasal spray is for intranasal use only. Seek emergency medical care immediately after use. Administer a single spray into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Do not administer more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
• Contraindications: REZENOPY^™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
• Warnings and Precautions:
  • Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
  • Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
  • Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
  • Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
• Adverse Reactions: The following adverse reactions were observed in a REZENOPY^™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
• Storage and Handling: Store REZENOPY^™ nasal spray in the blister and cartons provided. Store between 2°C to 25°C (36°F to 77°F). Excursions permitted up to 40°C (104°F). Do not freeze or expose to excessive heat above 40°C (104°F). Protect from light. REZENOPY^™ nasal spray may freeze at cold temperatures. If this happens, the device will not spray. If REZENOPY^™ nasal spray is frozen and is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.

For more detailed information, please refer to the full prescribing information provided by the FDA.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, such as ARBLI^™ and REZENOPY^™, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: [email protected]